A pharmacokinetic model of filgrastim and pegfilgrastim application in normal mice and those with cyclophosphamide-induced granulocytopaenia.
OBJECTIVE
Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is widely used as treatment for granulocytopaenia during cytotoxic chemotherapy; however, optimal scheduling of this pharmaceutical is unknown. Biomathematical models can help to pre-select optimal application schedules but precise pharmacokinetic properties of the pharmaceuticals are required at first. In this study, we have aimed to construct a pharmacokinetic model of G-CSF derivatives filgrastim and pegfilgrastim in mice.


METHODS
Healthy CD-1 mice and those with cyclophosphamide-induced granulocytopaenia were studied after administration of filgrastim and pegfilgrastim in different dosing and timing schedules. Close meshed time series of granulocytes and G-CSF plasma concentrations were determined. An ordinary differential equations model of pharmacokinetics was constructed on the basis of known mechanisms of drug distribution and degradation.


RESULTS
Predictions of the model fit well with all experimental data for both filgrastim and pegfilgrastim. We obtained a unique parameter setting for all experimental scenarios. Differences in pharmacokinetics between filgrastim and pegfilgrastim can be explained by different estimates of model parameters rather than by different model mechanisms. Parameter estimates with respect to distribution and clearance of the drug derivatives are in agreement with qualitative experimental results.


CONCLUSIONS
Dynamics of filgrastim and pegfilgrastim plasma levels can be explained by the same pharmacokinetic model but different model parameters. Beause of a strong clearance mechanism mediated by granulocytes, granulocytotic and granulocytopaenic conditions must be studied simultaneously to construct a reliable model. The pharmacokinetic model will be extended to a murine model of granulopoiesis under chemotherapy and G-CSF application.
Scholz
M
M
Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany. markus.scholz@imise.uni-leipzig.de
Ackermann
M
M
Engel
C
C
Emmrich
F
F
Loeffler
M
M
Kamprad
M
M
D000380:Agranulocytosis / Q000139:chemically induced*; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000009:adverse effects*; D004195:Disease Models, Animal; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000493:pharmacokinetics*; D051379:Mice; D008954:Models, Biological; D011092:Polyethylene Glycols; D011994:Recombinant Proteins
D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D003520:Cyclophosphamide; D000069585:Filgrastim
J Math Biol. 2005 Apr;50(4):397-439
15614553
Exp Hematol. 2008 Jan;36(1):9-16
17949891
Exp Hematol. 1995 Dec;23(14):1497-502
8542937
Biotechnol Prog. 2003 May-Jun;19(3):955-64
12790662
Curr Opin Hematol. 2007 Jan;14(1):3-8
17133093
Blood. 1989 Sep;74(4):1303-7
2475185
Cancer Res. 1991 Jul 15;51(14):3710-4
1712246
Inflamm Res. 2004 Aug;53 Suppl 2:S126-9
15338063
Pharmacol Res. 2004 Jul;50(1):55-8
15082029
Biocell. 2005 Apr;29(1):7-14
15954462
Ann Oncol. 2003 Jun;14(6):881-93
12796026
Eur J Cancer Care (Engl). 2004 Sep;13(4):371-9
15305906
Curr Med Res Opin. 2007 Sep;23(9):2283-95
17697451
Blood. 1988 Mar;71(3):640-5
2449922
Exp Hematol. 1997 Dec;25(13):1313-25
9406990
Drug Metab Rev. 1996 Nov;28(4):625-58
8959393
Anticancer Drugs. 2003 Apr;14(4):259-64
12679729
J Leukoc Biol. 1995 Jun;57(6):964-71
7540644
J Pharmacol Exp Ther. 1995 Jun;273(3):1114-22
7540687
Br J Cancer. 1988 Jul;58(1):64-9
2458748
Ann Oncol. 2008 Apr;19(4):752-62
18048382
Blood. 1994 Jan 1;83(1):119-27
8274731
Ann Oncol. 2008 May;19(5):1019; author reply 1019-20
18325914
Cancer Treat Rev. 2002 Apr;28 Suppl A:7-11
12173409
Cell Prolif. 2009 Dec;42(6):823-37
19780759
Blood. 1992 Oct 15;80(8):2012-20
1382715
Clin Cancer Res. 2001 Jul;7(7):2085-90
11448927
Blood. 1992 Jun 1;79(11):2849-54
1375115
Blood. 2004 Oct 15;104(8):2323-31
15226178
Biologics. 2009;3:27-37
19707393
J Pharmacokinet Pharmacodyn. 2001 Aug;28(4):321-42
11677930
Am J Physiol. 1995 Jul;269(1 Pt 1):E1-9
7543246
Semin Oncol. 2003 Aug;30(4 Suppl 13):3-9
14508714
Exp Hematol. 1999 Dec;27(12):1724-34
10641590
Blood. 1999 Apr 15;93(8):2506-14
10194429
J Pharm Sci. 2004 May;93(5):1367-73
15067712
Support Care Cancer. 2006 Sep;14(9):901-9
16622653
Br J Cancer. 1998 Mar;77(6):884-9
9528829
BioDrugs. 2008;22(5):315-29
18778113
Blood. 2003 Mar 1;101(5):1752-8
12393522
Mol Pharmacol. 2003 Jan;63(1):147-58
12488547
J Theor Biol. 2009 Mar 7;257(1):27-44
19007795
Oncology. 2006;70(4):290-3
16899982
Drugs. 2002;62 Suppl 1:89-98
12479597
J Clin Pharmacol. 2006 Jul;46(7):747-57
16809800
Br J Haematol. 1993 Oct;85(2):254-9
7506564
Clin Ther. 1998 Jul-Aug;20(4):722-36
9737832
Cancer. 2006 May 15;106(10):2258-66
16575919
Blood. 2006 Aug 1;108(3):812-20
16537807
Crit Rev Oncol Hematol. 2003 Oct 15;48(Suppl):S39-47
14563520
Blood. 1991 Dec 1;78(11):2791-808
1720034
Ann Oncol. 2002 Jun;13(6):903-9
12123336
Leuk Lymphoma. 2003 Sep;44(9):1503-8
14565651
Br J Haematol. 2006 Mar;132(6):723-35
16487172
Drug Metab Dispos. 2007 Dec;35(12):2211-7
17875672
Oncologist. 2005 Feb;10(2):138-49
15709216
Nat Rev Drug Discov. 2003 Mar;2(3):214-21
12612647
Science. 1986 Apr 4;232(4746):61-5
2420009
J Theor Biol. 2005 Jun 7;234(3):311-27
15784267
J Pharmacol Exp Ther. 1994 Dec;271(3):1535-43
7527856
Blood. 2001 Sep 1;98(5):1289-97
11520773
Proc Natl Acad Sci U S A. 1989 Dec;86(23):9499-503
2480603
Cancer Res. 1990 Oct 15;50(20):6615-9
1698539
Am J Hematol. 2003 Nov;74(3):149-55
14587040
Cell Prolif. 2003 Feb;36(1):27-34
12558658